Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

NCT00366678

Last updated date
Study Location
Albi, , 81000, France
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Vaccines, Pneumococcal
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
42-98 days
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy 2-month-old infants.

- Available for the entire study period.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


· Known contraindication to vaccines.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Vaccines, PneumococcalStudy to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
NCT00368966
  1. Ferrol, A Coruna
  2. Santiago de Compostela, A Coruna
  3. Argentona, Barcelona
  4. Sabadell, Barcelona
  5. Sant Adria de Besos, Barcelona
  6. Sant Cugat del Valles, Barcelona
  7. Sant Cugat del Valles, Barcelona
  8. Bilbao, Bizkaia
  9. Burela, Lugo
  10. Alcorcon, Madrid
  11. Fuenlabrada, Madrid
  12. Getafe, Madrid
  13. Getafe, Madrid
  14. Mostoles, Madrid
  15. Parla, Madrid
  16. Antequera, Malaga
  17. Pamplona, Navarra
  18. Vigo, Pontevedra
  19. Burjassot, Valencia
  20. La Eliana, Valencia
  21. Quart de Poblet, Valencia
  22. A Coruna,
  23. Almeria,
  24. Almeria,
  25. Almeria,
  26. Barcelona,
  27. Barcelona,
  28. La Coruna,
  29. Madrid,
  30. Madrid,
  31. Malaga,
  32. Ourense,
  33. Sevilla,
  34. Valencia,
  35. Valencia,
  36. Valencia,
  37. Valencia,
  38. Valencia,
  39. Valencia,
  40. Valencia,
  41. Valencia,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Vaccines, PneumococcalStudy Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
NCT00373958
  1. Fayetteville, Arkansas
  2. Jonesboro, Arkansas
  3. Little Rock, Arkansas
  4. Downey, California
  5. Fontana, California
  6. Loma Linda, California
  7. Paramount, California
  8. Riverside, California
  9. Centennial, Colorado
  10. Norwich, Connecticut
  11. Tampa, Florida
  12. Marietta, Georgia
  13. Woodstock, Georgia
  14. Chicago, Illinois
  15. Park Ridge, Illinois
  16. Overland Park, Kansas
  17. Bardstown, Kentucky
  18. Louisville, Kentucky
  19. Louisville, Kentucky
  20. Bronx, New York
  21. Rochester, New York
  22. Cincinnati, Ohio
  23. Cleveland, Ohio
  24. Mason, Ohio
  25. Latrobe, Pennsylvania
  26. Pittsburgh, Pennsylvania
  27. Pittsburgh, Pennsylvania
  28. Pittsburg, Pennsylvania
  29. Sellersville, Pennsylvania
  30. Wexford, Pennsylvania
  31. Charleston, South Carolina
  32. Jackson, Tennessee
  33. The Woodlands, Texas
  34. Murray, Utah
  35. Provo, Utah
  36. Richmond, Virginia
  37. Vienna, Virginia
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Vaccines, PneumococcalStudy to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
NCT00366340
  1. Bad Kreuznach,
  2. Bad Saulgau,
  3. Bad Sobernheim,
  4. Berlin,
  5. Berlin,
  6. Berlin,
  7. Berlin,
  8. Berlin,
  9. Berlin,
  10. Birkenfeld,
  11. Bobingen,
  12. Bramsche,
  13. Bretten,
  14. Cham,
  15. Ehingen,
  16. Erlangen,
  17. Eschwege,
  18. Flensburg,
  19. Gau-Odernheim,
  20. Hamburg,
  21. Herzogenaurach,
  22. Hoechberg,
  23. Kehl,
  24. Kiel,
  25. Kleve,
  26. Krefeld,
  27. Ludwigshafen,
  28. Luebeck,
  29. Mainz,
  30. Metzingen,
  31. Minden,
  32. Muenster,
  33. Muenster,
  34. Neumuenster,
  35. Neumünster,
  36. Neustadt/Aisch,
  37. Niebuell,
  38. Nuernberg,
  39. Nuernberg,
  40. Oberkirch,
  41. Olching,
  42. Pforzheim,
  43. Porta Westfalica,
  44. Ravensburg,
  45. Tettnang,
  46. Vellmar,
  47. Weiden,
  48. Weilheim,
  49. Welzheim,
  50. Wiesbaden,
  51. Zirndorf,
ALL GENDERS
56 Days+
years
MULTIPLE SITES
Vaccines, PneumococcalStudy to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00366678
  1. Albi,
  2. Amiens,
  3. Ancenis,
  4. Blanquefort,
  5. Bondues,
  6. Bordeaux,
  7. Brest,
  8. Chalons en champagne,
  9. Creteil,
  10. Dijon,
  11. Draguignan,
  12. Ecully,
  13. Essey-les-nancy,
  14. Floirac,
  15. Frejus,
  16. Garges-les-Gonesse,
  17. Illkirch,
  18. Joue les tours,
  19. Le havre,
  20. Le plessis-trevise,
  21. Le pontet,
  22. Les lilas,
  23. Les sables d'olonne,
  24. Libourne,
  25. Lingolsheim,
  26. Lyon,
  27. Lyon,
  28. Marcq en baroeul,
  29. Maromme,
  30. Moutiers,
  31. Nancy,
  32. Nice,
  33. Nogent sur marne,
  34. Nogent-sur-marne,
  35. Oullins,
  36. Paris,
  37. Rouen,
  38. Strasbourg,
  39. Strasbourg,
  40. Thionville,
  41. Tours,
  42. Tresses melac,
  43. Vandoeuvre les nancy,
  44. Vaulx-en-velin,
  45. Villeneuve d'ascq,
  46. Vitry-sur-seine,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
Official Title  ICMJE A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.
Brief Summary The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccines in France.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Vaccines, Pneumococcal
Intervention  ICMJE
  • Biological: 13-valent pneumococcal conjugate vaccine
    Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
  • Biological: 7-valent pneumococcal conjugate vaccine
    Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
  • Drug: Pentavac
    The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
Study Arms  ICMJE
  • Experimental: 13-valent pneumococcal conjugate vaccine
    13-valent pneumococcal conjugate vaccine
    Interventions:
    • Biological: 13-valent pneumococcal conjugate vaccine
    • Drug: Pentavac
  • Active Comparator: 7-valent pneumococcal conjugate vaccine
    7-valent pneumococcal conjugate vaccine
    Interventions:
    • Biological: 7-valent pneumococcal conjugate vaccine
    • Drug: Pentavac
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 6, 2012)
613
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE November 2008
Actual Primary Completion Date November 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy 2-month-old infants.
  • Available for the entire study period.

Exclusion criteria:

· Known contraindication to vaccines.

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 42 Days to 98 Days   (Child)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00366678
Other Study ID Numbers  ICMJE 6096A1-008
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Wyeth is now a wholly owned subsidiary of Pfizer
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator:Trial ManagerFor France, [email protected]
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP